medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Oct. 7, 2023
Abstract
Background
Systemic
chronic
inflammation
plays
a
role
in
the
pathophysiology
of
both
heart
failure
with
preserved
ejection
fraction
(HFpEF)
and
metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD).
Aim
This
study
aimed
to
investigate
whether
serum
high-sensitivity
C-reactive
protein
(hs-CRP)
levels
were
associated
future
risk
(HF)
hospitalization
patients
MAFLD
normal
left
ventricular
(LVEF).
Methods
The
enrolled
consecutive
individuals
LVEF
who
underwent
coronary
angiography
for
suspected
disease.
population
was
subdivided
into
non-HF,
pre-HFpEF,
HFpEF
groups
at
baseline.
outcome
first
HF.
Results
In
10,019
middle-aged
(mean
age
63.3±10.6
years;
38.5%
female),
prevalence
rates
pre-HFpEF
34.2%
34.5%,
median
hs-CRP
level
4.5
mg/L
(IQR:
1.9-10
mg/L)
5.0
2.1-10.1
mg/L),
respectively.
Serum
significantly
higher
than
non-HF
group.
HF
hospitalizations
occurred
1942
(19.4%)
over
3.2
years,
3.7%
20.8%
32.1%
HFpEF,
Cox
regression
analyses
showed
that
highest
quartile
had
∼4.5-fold
increased
being
hospitalized
compared
those
lowest
(adjusted-Hazard
Ratio
4.42,
95%
CI
3.72-5.25).
Conclusions
There
high
baseline
subjects
MAFLD.
an
elevated
levels.
Diabetes & Metabolism,
Journal Year:
2023,
Volume and Issue:
50(1), P. 101506 - 101506
Published: Dec. 21, 2023
With
the
rising
tide
of
fatty
liver
disease
related
to
metabolic
dysfunction
worldwide,
association
this
common
with
chronic
kidney
(CKD)
has
become
increasingly
evident.
In
2020,
more
inclusive
term
dysfunction-associated
(MAFLD)
was
proposed
replace
old
nonalcoholic
(NAFLD).
2023,
a
modified
Delphi
process
led
by
three
large
pan-national
associations.
There
consensus
change
nomenclature
and
definition
include
presence
at
least
one
five
cardiometabolic
risk
factors
as
diagnostic
criteria.
The
name
chosen
NAFLD
steatotic
(MASLD).
from
MAFLD
then
MASLD
resulted
in
reappraisal
epidemiological
trends
associations
developing
CKD.
observed
between
MAFLD/MASLD
CKD
our
understanding
that
can
be
an
epiphenomenon
linked
underlying
support
notion
individuals
are
substantially
higher
incident
than
those
without
MASLD.
This
narrative
review
provides
overview
literature
on
(a)
evolution
criteria
for
diagnosing
highly
prevalent
disease,
(b)
evidence
linking
CKD,
(c)
mechanisms
which
(and
strongly
MASLD)
may
increase
(d)
potential
drug
treatments
benefit
both
Journal of the American Heart Association,
Journal Year:
2024,
Volume and Issue:
13(3)
Published: Jan. 19, 2024
Systemic
chronic
inflammation
plays
a
role
in
the
pathophysiology
of
both
heart
failure
with
preserved
ejection
fraction
(HFpEF)
and
metabolic
dysfunction-associated
fatty
liver
disease.
This
study
aimed
to
investigate
whether
serum
hs-CRP
(high-sensitivity
C-reactive
protein)
levels
were
associated
future
risk
(HF)
hospitalization
patients
disease
normal
left
ventricular
fraction.
Metabolism and Target Organ Damage,
Journal Year:
2024,
Volume and Issue:
4(3)
Published: June 26, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
stands
as
an
independent
risk
factor
for
cardiovascular
(CVD),
which
is
the
leading
cause
of
mortality
among
MASLD
patients.
The
diverse
spectrum
cardio-nephro-metabolic
and
vascular
manifestations
inherent
in
highlights
complex
profile
CVD
associated
with
this
condition.
However,
current
approaches
to
assessing
lack
specificity,
predominantly
relying
on
traditional
markers.
Although
it
widely
accepted
that
patients
advanced
fibrosis
are
more
prone
risk,
recent
evidence
suggests
isolated
focus
may
overlook
remarkable
phenotypic
variability
across
entire
population.
Emerging
data
indicate
a
progressive
escalation
parallel
severity
MASLD,
highlighting
need
precise
staging
inform
accurate
assessment.
To
address
challenge,
we
propose
novel
sequential
approach
assessment
MASLD.
While
factors
remain
essential,
incorporating
liver-specific
parameters
enhances
stratification
guides
targeted
interventions
mitigate
substantial
burden
vulnerable
This
involves
initial
screening
using
FIB-4
NAFLD
score,
followed
by
imaging-based
non-invasive
techniques
individuals
at
intermediate-high
fat
quantification
low-risk
individuals.
Future
prospective
investigations
should
simultaneous
use
biomarkers
imaging
modalities
evaluate,
sex-specific
manner,
efficacy
proposed
determine
optimal
thresholds
steatosis
European Journal of Preventive Cardiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 14, 2024
Abstract
Aims
Although
prior
observational
studies
have
suggested
that
patients
with
non-alcoholic
fatty
liver
disease
(NAFLD)
may
a
higher
risk
of
coronary
artery
calcification
(CAC),
these
findings
remain
controversial.
This
study
aimed
to
explore
the
causal
association
between
NAFLD
and
CAC
at
genetic
level
by
two-sample
Mendelian
randomization
(MR)
analysis.
Methods
results
Utilizing
summary-level
data
from
multiple
large-scale
genome-wide
in
European
populations,
MR
analysis
was
initially
conducted
potential
CAC.
The
were
pooled
through
random-effect
meta-analysis.
inverse
variance
weighting
method
served
as
primary
approach
for
Additionally,
weighted
median,
MR-Egger,
MR-pleiotropy
residual
sum
outlier
methods
applied
sensitivity
Summary-level
on
content
utilized
validation
analysis,
while
cirrhosis
positive
control,
further
ensuring
validity
robustness
our
findings.
Reverse
performed
assess
NAFLD,
employing
instrument
variables
derived
indicated
genetically
predicted
had
no
effects
[Beta:
0.01,
95%
confidence
interval
(CI):
−0.02
0.03,
P
=
0.74].
Likewise,
reverse
found
significant
(odds
ratio:
1.00,
CI:
0.96–1.06,
0.88).
Validation
yielded
consistent
results,
showing
Conclusion
Our
did
not
support
there
is
level.
reported
some
previous
rely
complicated
metabolic
disorders,
rather
than
being
directly
linked
hepatic
steatosis.
